Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open Label Study to Evaluate Safety, Tolerability and Immunogenicity of Multiple Combinations of H1 and H5 Influenza Hemagglutinin Plasmids Administered ID Followed by in Vivo Electroporation With CELLECTRA®-3P in Healthy Adults

NCT01405885 is registered in ClinicalTrials.gov with Inovio Pharmaceuticals as lead sponsor.

NCT NCT01405885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01405885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open Label Study to Evaluate Safety, Tolerability and Immunogenicity of Multiple Combinations of H1 and H5 Influenza Hemagglutinin Plasmids Administered ID Followed by in Vivo Electroporation With CELLECTRA®-3P in Healthy Adults
Lead sponsor
Inovio Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2011
Completion date
August 31, 2013
Enrollment
116 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy